share_log

Johnson & Johnson | 10-Q: Q3 2024 Earnings Report

Johnson & Johnson | 10-Q: Q3 2024 Earnings Report

強生 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/23 15:05

Moomoo AI 已提取核心訊息

Johnson & Johnson reported Q3 2024 revenue of $22.5 billion, up 5.2% year-over-year, with operational growth of 6.3% partially offset by a 1.1% negative currency impact. Innovative Medicine sales rose 4.9% to $14.6 billion, while MedTech revenue increased 5.8% to $7.9 billion. The quarter included a $1.25 billion charge for acquiring NM26 bispecific antibody rights.Net earnings declined to $2.7 billion from $4.3 billion in Q3 2023, primarily due to $2.0 billion in talc-related charges. The company recorded strong performance in key products, with DARZALEX sales up 20.7% to $3.0 billion and TREMFYA growing 13.0% to $1.0 billion. The MedTech segment was boosted by the Shockwave acquisition and double-digit growth in Electrophysiology.Looking ahead, J&J maintained its operational sales growth outlook and continues to pursue resolution of talc claims through multiple pathways. The company's financial position remains strong with $20.0 billion in cash and cash equivalents. The Board declared a quarterly dividend of $1.24 per share, demonstrating continued commitment to shareholder returns despite ongoing litigation challenges.
Johnson & Johnson reported Q3 2024 revenue of $22.5 billion, up 5.2% year-over-year, with operational growth of 6.3% partially offset by a 1.1% negative currency impact. Innovative Medicine sales rose 4.9% to $14.6 billion, while MedTech revenue increased 5.8% to $7.9 billion. The quarter included a $1.25 billion charge for acquiring NM26 bispecific antibody rights.Net earnings declined to $2.7 billion from $4.3 billion in Q3 2023, primarily due to $2.0 billion in talc-related charges. The company recorded strong performance in key products, with DARZALEX sales up 20.7% to $3.0 billion and TREMFYA growing 13.0% to $1.0 billion. The MedTech segment was boosted by the Shockwave acquisition and double-digit growth in Electrophysiology.Looking ahead, J&J maintained its operational sales growth outlook and continues to pursue resolution of talc claims through multiple pathways. The company's financial position remains strong with $20.0 billion in cash and cash equivalents. The Board declared a quarterly dividend of $1.24 per share, demonstrating continued commitment to shareholder returns despite ongoing litigation challenges.
強生在2024年第三季度報告的營業收入爲225億，同比增長5.2%，運營增長爲6.3%，部分受到1.1%的負貨幣影響影響。創新醫學銷售增長4.9%，達到146億，而醫療技術營收增長5.8%，達到79億。本季度包括收購NM26雙特異性抗體權利的125億費用。淨收益從2023年第三季度的43億下降至27億，主要由於與滑石粉相關的20億費用。公司主要產品表現強勁，DARZALEX銷售增長20.7%，達到30億，TREMFYA增長13.0%，達到10億。醫療技術部門受益於Shockwave收購和電生理領域的兩位數增長。展望未來，強生維持其運營銷售增長前景，並繼續通過多種途徑追求對滑石粉索賠的解決。公司的財務狀況依然強勁，現金及現金等價物爲200億。董事會宣佈每股1.24美元的季度股息，儘管面臨持續的訴訟挑戰，仍表現出對股東回報的持續承諾。
強生在2024年第三季度報告的營業收入爲225億，同比增長5.2%，運營增長爲6.3%，部分受到1.1%的負貨幣影響影響。創新醫學銷售增長4.9%，達到146億，而醫療技術營收增長5.8%，達到79億。本季度包括收購NM26雙特異性抗體權利的125億費用。淨收益從2023年第三季度的43億下降至27億，主要由於與滑石粉相關的20億費用。公司主要產品表現強勁，DARZALEX銷售增長20.7%，達到30億，TREMFYA增長13.0%，達到10億。醫療技術部門受益於Shockwave收購和電生理領域的兩位數增長。展望未來，強生維持其運營銷售增長前景，並繼續通過多種途徑追求對滑石粉索賠的解決。公司的財務狀況依然強勁，現金及現金等價物爲200億。董事會宣佈每股1.24美元的季度股息，儘管面臨持續的訴訟挑戰，仍表現出對股東回報的持續承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！